YOLFTbeta
ABVC Biopharma Inc

ABVC Biopharma Inc

ABVC · NASDAQ · Healthcare / Biotechnology

0.91USD-0.05 (-5.56%)

Price History

Full chart

Market Stats

Previous Close0.9636
Open0.97
Day Range0.861 – 0.98
52-Week Range0.707 – 3.40
Volume37.46K
Market Cap29.05M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.29
Dividend Yield0.00%
Beta0.61
50-Day Avg1.01
200-Day Avg1.41

About

ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus, which is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer; ABV-2001, an intraocular irrigation solution; ABV-2002, a corneal Storage Solution; and ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer. The company has a co-development agreement with Rgene Corporation and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Uttam Yashwant Patil Ph.D.
  • Employees16
  • Headquarters44370 Old Warm Springs Boulevard, Fremont, CA, United States, 94538, USA
  • Websitehttps://www.abvcpharma.com

Leadership

  • Mr. Eugene JiangChairman & Chief Business Officer · b. 1986
  • Dr. Uttam Yashwant Patil Ph.D.CEO & Interim CFO · b. 1986
  • Dr. Tsung-Shann Jiang EMBA, Ph.D.Chief Scientific Officer, Chief Strategy Officer & Director · b. 1954

Financials

Income Statement

Currency: USD2002-12-312003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue10.00K13.67K57.49K17.08K41.84K41.67K25.09K-272.00K14.86K3.19K7.79K3.36K323.20K6.96K701.72K483.05K355.80K969.78K152.43K509.59K795.95K
Growth (%)-+36.70%+320.59%-70.29%+144.90%-0.41%-39.78%-1184.01%+105.46%-78.53%+144.11%-56.85%-99.05%+9887.50%+117.65%+9987.97%-31.16%-26.34%+172.57%-84.28%+234.31%+56.19%
Cost of Revenue10.00K25.76K32.39K408-12.76K37.49K1.53M45.25K34.18K-521322.25K228.89K20.14K18.72K5.09K286.42K302.04K763504.83K
Gross Profit--12.09K25.10K16.68K41.84K28.91K-12.39K-1.53M-30.39K-30.99K7.79K2.84K-32947-221.93K681.58K464.33K350.71K683.37K-149.61K508.83K795.95K
Gross Margin--88.42%43.66%97.61%100.00%69.38%-49.39%561.10%-204.50%-971.44%100.00%84.49%-100.00%29.63%-3190.54%97.13%96.13%98.57%70.47%-98.15%99.85%100.00%
Operating Expense-11.72K23.10K34.25K68.66K4.44M5.34M3.38M1.86M1.86M31.89K35.12K11.00M4.14M2.56M4.14M8.97M12.06M15.80M6.62M5.21M7.95M
Operating Income-20.00K-23.80K2.01K-17.57K-26.82K-4.42M-5.35M-4.91M-1.89M-1.89M-24.10K-32.28K-11.00M-4.14M-2.78M-3.46M-8.51M-11.71M-15.11M-6.77M-4.71M-7.15M
Operating Margin-200.00%-174.13%3.49%-102.86%-64.12%-10596.38%-21340.32%1805.32%-12715.16%-59180.66%-309.49%-960.74%-34366359.38%-129497.81%-40031.10%-492.90%-1760.87%-3290.07%-1558.54%-4439.24%-923.34%-898.46%
EBITDA-20.00K-23.80K2.58K-17.57K-26.82K-4.38M-5.31M-4.87M-1.64M-979.55K-24.10K-32.28K-11.00M-4.09M-5.92M-3.47M-10.37M-10.97M-15.20M-6.33M-4.34M-7.43M
EBITDA Margin-200.00%-174.13%4.48%-102.86%-64.12%-10515.51%-21167.87%1788.70%-11017.80%-30706.99%-309.49%-960.74%-34364793.75%-128115.58%-85153.41%-494.95%-2147.16%-3083.68%-1567.03%-4153.24%-852.21%-933.74%
Net Income-20.00K-25.36K2.54K-26.67K-25.40K-4.65M-6.77M-5.18M-1.90M-1.22M-24.10K-32.28K-11.01M-4.24M-5.58M-3.64M-9.79M-12.84M-16.42M-7.79M-4.90M-7.91M
Net Income Margin-200.00%-185.54%4.42%-156.11%-60.71%-11161.73%-26981.99%1905.22%-12793.14%-38202.23%-309.49%-960.74%-34399184.38%-132755.32%-80152.08%-518.98%-2026.97%-3608.47%-1693.50%-5109.26%-962.12%-993.60%
R&D-----------10.00M10.00M3.17M988.72K1.05M549.66K1.00M2.69M1.06M179.27K121.08K
R&D as % of Total Revenue-----------297619.05%31250000.00%99238.58%14213.93%149.43%113.79%282.13%277.74%697.31%35.18%15.21%
Interest Expense01.56K361.21K1.43K256.51K1.42M271.86K218.57K204.92K49.09K010.17K103.46K462.75K482.01K405.03K227.21K293.97K1.31M825.90K415.89K
Interest Expense % of Total Revenue0.00%11.40%0.06%7.10%3.41%615.61%5664.73%-99.95%1470.86%6423.73%630.45%0.00%31781.25%3237.17%6652.54%68.69%83.85%63.86%30.31%861.82%162.07%52.25%

Balance Sheet

Currency: USD2002-12-312003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets40.00K110.00K90.31K63.40K88.34K1.20M1.50M518.17K293.94K369.40K64.59K68.23K18.64K6.60M96.27K6.93M14.77M13.70M10.93M7.78M7.54M21.06M
Total Liabilities30.00K30.00K2.96K2.72K53.07K913.84K2.74M2.53M3.29M1.83M34.03K39.15K6.54M4.14M5.85M7.05M8.94M4.83M6.34M6.53M6.82M7.76M
Total Equity10.00K80.00K87.34K60.67K35.27K290.29K-1.24M-2.01M-2.99M-1.46M30.56K29.08K-6.52M1.65M-5.75M-150.96K6.60M8.84M4.45M1.55M1.23M11.11M
Cash-110.00K81.82K63.40K87.85K808.16K974.28K-2.81K71.78K6183.36K18.64K256.93K40.04K144.29K5.00M5.83M1.39M716.78K863.82K681.48K
Total Debt30.00K10.00K---428.55K1.14M840.22K1.41M1.15M7.00K7.00K-1.23M800.00K4.58M6.77M3.34M3.41M2.77M3.20M3.47M
Net Debt30.00K-100.00K-81.82K-63.40K-87.85K-379.61K163.33K840.22K1.41M1.08M7.00K3.64K-18.64K969.20K759.96K4.44M1.77M-2.49M2.02M2.05M2.34M2.79M

Cash Flow

Currency: USD2002-12-312003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312014-12-312015-12-312016-12-312017-09-302017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-10.00K355-7.45K-18.43K24.45K-2.69M-2.34M-1.56M-1.05M-1.59M1.17K3.36K-3.47M-1.60M-1.68M-630.20K-3.13M-4.56M-7.60M-7.40M-4.19M-1.81M-2.99M
Investing Cash Flow------97.56K-215.94K-59.44K-11.37K-38.74K-19.55K--156.37K-156.37K-7.49M-156.37K-35.30K-225.43K-805.97K-1.72M-360.19K--1.21M
Financing Cash Flow10.00K103.21K-15.49K--2.86M2.72M641.12K1.06M1.70M-1.79K995.54K2.65M1.63M9.33M593.00K3.09M9.57M10.00M4.01M3.87M1.98M4.64M
Capital Expenditure0000097.56K215.94K59.44K11.37K41.74K19.55K000017.50K17.50K17.50K17.50K119.69K21.20K55.79K
Free Cash Flow-10.00K355-7.45K-18.43K24.45K-2.79M-2.55M-1.62M-1.06M-1.63M1.17K3.36K-3.47M--1.68M-630.20K-3.13M-4.56M-7.62M-7.52M-4.21M-1.81M-2.99M
Dividends Paid------------0000-------
FCF to OCF100.00%100.00%100.00%100.00%100.00%103.62%109.24%103.82%101.09%102.62%100.00%100.00%100.00%-100.00%100.00%100.00%100.00%100.23%101.62%100.51%100.00%100.00%
Dividend Paid to FCF------------0.00%-0.00%0.00%-------

Earnings

Report DateDec 31, 2004Mar 31, 2005Jun 30, 2005Sep 30, 2006Dec 31, 2006Mar 31, 2007Jun 30, 2007Sep 30, 2007May 28, 2008Sep 3, 2008Dec 3, 2008Feb 25, 2009Apr 28, 2009Aug 27, 2009Dec 2, 2009Mar 3, 2010May 20, 2010Aug 16, 2010Dec 1, 2010Mar 2, 2011May 19, 2011Aug 15, 2011Nov 30, 2011Feb 29, 2012May 17, 2012Aug 13, 2012Nov 28, 2012Feb 27, 2013May 23, 2013Aug 12, 2013Nov 27, 2013Feb 26, 2014May 22, 2014Aug 18, 2014Dec 31, 2014Feb 25, 2015May 21, 2015Aug 17, 2015Dec 31, 2015Mar 31, 2016Jun 30, 2016Sep 30, 2016Nov 30, 2016Mar 31, 2017Jun 30, 2017Sep 30, 2017Dec 31, 2017Mar 31, 2018Jun 30, 2018Sep 30, 2018Dec 31, 2018Mar 31, 2019Jun 30, 2019Sep 30, 2019Dec 31, 2019Mar 31, 2020Jun 29, 2020Aug 14, 2020Nov 17, 2020Mar 16, 2021May 10, 2021Aug 12, 2021Nov 15, 2021Mar 31, 2022May 16, 2022Aug 15, 2022Nov 14, 2022Mar 31, 2023May 15, 2023Aug 14, 2023Nov 15, 2023Mar 13, 2024May 17, 2024Aug 14, 2024Nov 13, 2024Apr 15, 2025Aug 13, 2025Nov 3, 2025Aug 12, 2026Oct 30, 2026
EPS Estimate--------------------------------------------0.00---------------1.00--0.40-0.40-0.40-0.20-1.25-2.00-0.15-0.50-0.06-0.04----0.000.000.00--
EPS Actual-5743.88-7942.95-3401.56-21347.40-17857.35-23068.42-71223.91-95976.04-80602.89-101290.97-42979.94-122410.01-39216.50-32762.89-35832.23-72237.33-32318.87-11042.39-18394.08-18849.93-19628.50-31422.23-20196.46-8325.48-9293.91-3514.27-976.22-824.81-564.87-206.050.00-0.05-0.16-0.16-0.00-5.415.87-7.87-0.38-0.57-0.03-0.15-9.10-0.02-0.02-0.36-0.03-0.05-0.05-0.05-0.32-0.05-0.03-0.06-0.06-0.06-0.09-0.09-0.09-2.43-0.05-0.80-0.70-3.10-0.20-0.60-1.10-0.15-0.60-0.68-0.82-0.39-0.40-0.09-0.010.02-0.13-0.05-0.03-
Surprise------------------------------------------------------------143.00%--100.00%-75.00%-675.00%0.00%52.00%45.00%0.00%-20.00%-1040.17%-1945.25%---------
Timing--------------------------------------------------------After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursPre-market-----

Key Statistics & Ratios

Market Cap29.05M
Enterprise Value32.91M
Trailing P/E0.00
Forward P/E0.00
Price / Sales111.69
Price / Book2.95
EPS-0.29
Book Value0.404
Revenue (TTM)797.92K
Gross Profit (TTM)797.92K
EBITDA-6.49M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-69.86%
Return on Assets-22.85%
Shares Outstanding26.65M
Shares Float21.10M
Beta0.61
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Hold
Based on 1 analystsTarget 2.02
  • Hold
    1

Ownership Breakdown

Institutions
4.09%
Insiders
18.11%
Retail / Other
77.80%

Top Institutional Holders

  • Geode Capital Management, LLC
    221.17K0.83%
  • Vanguard Capital Management, LLC
    190.57K0.71%
  • Vanguard Fiduciary Trust Co
    97.36K0.37%
  • Renaissance Technologies Corp
    95.10K0.36%
  • State Street Corp
    72.80K0.27%
  • Citadel Advisors Llc
    72.09K0.27%
  • BlackRock Inc
    56.44K0.21%
  • Panagora Asset Management Inc
    36.68K0.14%
  • Northern Trust Corp
    32.09K0.12%
  • TWO SIGMA SECURITIES, LLC
    21.02K0.08%
  • Squarepoint Ops LLC
    10.55K0.04%
  • Tower Research Capital LLC
    5.42K0.02%
  • UBS Group AG
    1.77K0.01%
  • LifeSteps Financial, Inc.
    3000.00%
  • Royal Bank of Canada
    170.00%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    360.87K1.35%
  • Fidelity Extended Market Index
    109.47K0.41%
  • Fidelity Series Total Market Index
    35.53K0.13%
  • Fidelity Total Market Index
    31.05K0.12%
  • Fidelity Nasdaq Composite Index
    14.82K0.06%

Stock Splits

  • Jul 25, 20231:10
  • May 8, 20191:18
  • Apr 11, 2016314:100
  • Aug 13, 20151:5000
  • Feb 18, 20111:5
  • Jun 19, 20071573:1000